Clinical Trials
28 trialsNCT04083599 2026-06-02
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT06535607 2026-05-26
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT06378177 2026-05-19
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
Phase 2 Active not recruiting
NCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT06385080 2026-05-08
OrigAMI-4
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06332092 2026-03-16
HNSCC
Fulgent Pharma LLC.
Phase 2 Active not recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT06727565 2026-03-02
VELOCITY-HNSCC
Gilead Sciences
Phase 2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT04428151 2025-12-04
LEAP-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06699212 2025-10-15
ECLIPSE
Rakuten Medical, Inc.
Phase 3 Recruiting
NCT05054439 2025-09-26
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT05459129 2025-09-15
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03440437 2025-07-01
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
invoX Pharma Limited
Phase 1/2 Terminated
NCT04489888 2025-06-19
MK-3475-B10
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT06943820 2025-06-03
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
Phase 1/2 Recruiting
NCT05743270 2025-03-11
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Replimune, Inc.
Phase 2 Withdrawn
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT04843098 2024-12-09
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Junde Biotechnology Co., Ltd
Phase 1/2 Active not recruiting
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT06062602 2023-10-06
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT05783921 2023-07-28
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT01852292 2018-07-24
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Phase 2 Terminated
NCT01166542 2014-11-05
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Oncolytics Biotech
Phase 3 Completed
NCT00753038 2014-11-04
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Oncolytics Biotech
Phase 2 Completed